Papers/PMID:38850440
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
Endocrine2024The record
5 findings · 1 compound · 5 endpoints
What it reported
How to read these marksWhat moved
5 findings
tirzepatide — decreases systolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“As shown in Figure S6 and Table S3, all tirzepatide doses significantly reduced systolic blood pressure (SBP) compared to placebo.”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink
tirzepatide — decreases glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“All three tirzepatide doses were associated with a significant decrease in HbA1c levels compared to placebo (Figure S8 and Table S3).”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink
tirzepatide — decreases fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“As shown in Figure S9 and Table S3, all tirzepatide doses resulted in a significant reduction in FPG levels compared to placebo.”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink
tirzepatide — decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The pooled data analysis showed substantial weight reduction in all three tirzepatide doses compared to the placebo group.”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in seven placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink
tirzepatide — decreases total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“All three doses of tirzepatide significantly decreased TC: −0.25 mmol/L(95% CI:−0.34, −0.15; P <0.00001, high certainty) for 5 mg, −0.30 mmol/L(95% CI:−0.40, −0.20;P <0.00001, high certainty) for 10 mg, and −0.37 mmol/L(95% CI:−0.49, −0.24; P < 0.00001, moderate certainty) for 15 mg.”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink